Era of corticosteroids in dermatology: efficiency and safety of klobetasol propionate 0.05% in various dermatosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article highlights the issues of efficiency and safety of superpotent topical glucocorticosteroid (GCS) - clobetasol propionate. In terms of strength and effectiveness in steroid-sensitive dermatoses, it is superior to the majority of topical corticosteroids. The drug has several dosage forms that are convenient for use in various localizations. It is a drug of choice in the treatment of moderate and severe psoriasis, and is effective in the treatment of a wide range of dermatoses that are difficult to treat with less active corticosteroids. Clobetasol propionate is safe with the rational use. The development of serious complications is possible with prolonged use at very high doses.

Full Text

Restricted Access

About the authors

L. S Kruglova

Central State Medical Academy

Email: kruglovals@mail.ru

M. A Petriy

Central State Medical Academy

E. M Gensler

Central State Medical Academy

References

  1. Вольф К., Голдсмит Л.А., Кац С.И. и др. Дерматология Фицпатрика в клинической практике: В 3 т. Пер с англ. Под ред. А.А. Кубановой. М., 2013. Т. 3. С. 2291-96
  2. Харкевич Д.А. Фармакология. 10-е изд. М., 2010. 908 с
  3. Weston W.L. The use and abuse of topical steroids. Contemp Pediatr. 1988;5:57-66.
  4. Camarasa J.G., Gimenez-Arnau A. Глюкокортикоиды местные. В кн.: Европейское руководство по лечению дерматологических заболеваний. Под ред. А.Д. Кацамбаса, Т. М. Лотти. М., 2009. С. 638-51.
  5. Jacobson C., Cornell R.C., Savin R.C. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0,05 percent ointment in the treatment of psoriasis. Cutis. 1986;37(3):213-14, 216, 218-20.
  6. Lee F.W, Nystrom D.D., Kooce W. Comparison of the percutaneous absorption of fluticasone 17-propionate from cream and ointment formulation in rats. Pharm Res. 1989;6(Suppl.):106.
  7. Батыршина С.В. Глюкокортикостероиды для местного применения в современной стратегии терапии воспалительных дерматозов в педиатрической практике. Практическая медицина. 2014;9(85) 94-102.
  8. Бакулев А.Л., Кравченя С.С. Об эффективности и безопасности применения клобетазола пропионата коротким курсом у больных псориазом в фазе прогрессирования. Вестник дерматологии и венерологии. 2012;3:121-25
  9. Хлебникова А.Н. Современные подходы к наружной терапии псориаза. Вестник дерматологии и венерологии. 2012;1:86-91
  10. Zampetti A., Barone A., Antuzzi D., et al. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years. J Dermatol Treat. 2008;19(3):134-40. doi: 10.1080/09546630701846087.
  11. Guttman-Yassky E., Ungar B., Malik K., et al. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. J Allergy Clin Immunol. 2017;140(4):1032-42.e13. Doi: 10.1016/j. jaci.2017.01.027.
  12. Olsen E.A., Cornell R.C., et al., Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol. 1986;15:246-55. doi: 10.1016/s0190-9622(86)70164-3.
  13. Goh C.L., Lim J.T., et al. The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema. Med J. 1999;40(5):341-44.
  14. Нажмутдинова Д.К. Клобетазол в терапии красного плоского лишая. Вестник дерматологии и венерологии. 2011;1:81-2.
  15. Anderson K., Ascanio N., Kinney M. A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class 1 topical corticosteroid and topical calcineurin inhibitor. J Dermatol Treat. 2016;27(1):64-6. doi: 10.3109/09546634.2015.1054777.
  16. Madan V., August P.J., Chalmers R.J.G. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study Clin Exp Dermatol. 2010;35(1):27-30. doi: 10.1111/j.1365-2230.2009.03351.x.
  17. Sara G.A. van Velsen, Marlise P, et al. The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. J Dermatol Treat. 2012;23:16-20. doi: 10.3109/09546634.2010.534127.
  18. Josse G., Rouvrais C., Mas A., et al. A multitechnique evaluation of topical corticosteroid treatment. Skin Res Technol. 2009;15(1):35-9. doi: 10.1111/j.1600-0846.2008.00326.x.
  19. Kao J.S., Fluhr J.W., Man M.Q., et al., Shortterm glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456-64. doi: 10.1046/j.1523-1747.2003.12053.x.
  20. Хлебникова А.Н. Клобетазола пропионат (Дермовейт) - новые возможности в терапии дерматозов. Вестник дерматологии и венерологии. 2010;5:124-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies